Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth By: Benzinga via Benzinga January 22, 2015 at 11:54 AM EST Johnson & Johnson (NYSE: JNJ) is entering a "trough year" for its all-important pharmaceuticals segment, an analyst ... Read More >> Related Stocks: Johnson & Johnson